Year |
Citation |
Score |
2018 |
Clapper JR, Henry CL, Niphakis MJ, Knize AM, Coppola AR, Simon GM, Ngo N, Herbst RA, Herbst DM, Reed AW, Cisar JS, Weber OD, Viader A, Alexander JP, Cunningham ML, et al. Monoacylglycerol Lipase Inhibition in Human and Rodent Systems Supports Clinical Evaluation of Endocannabinoid Modulators. The Journal of Pharmacology and Experimental Therapeutics. PMID 30305428 DOI: 10.1124/Jpet.118.252296 |
0.359 |
|
2018 |
Cisar JS, Weber OD, Clapper JR, Blankman J, Henry CL, Simon GM, Alexander JP, Jones TK, Ezekowitz RAB, O'Neill GP, Grice CA. Identification of ABX-1431, a Selective Inhibitor of Monoacylglycerol Lipase and Clinical Candidate for Treatment of Neurological Disorders. Journal of Medicinal Chemistry. PMID 30067909 DOI: 10.1021/Acs.Jmedchem.8B00951 |
0.509 |
|
2012 |
Jung KM, Clapper JR, Fu J, D'Agostino G, Guijarro A, Thongkham D, Avanesian A, Astarita G, DiPatrizio NV, Frontini A, Cinti S, Diano S, Piomelli D. 2-arachidonoylglycerol signaling in forebrain regulates systemic energy metabolism. Cell Metabolism. 15: 299-310. PMID 22405068 DOI: 10.1016/J.Cmet.2012.01.021 |
0.64 |
|
2011 |
Vacondio F, Silva C, Lodola A, Carmi C, Rivara S, Duranti A, Tontini A, Sanchini S, Clapper JR, Piomelli D, Tarzia G, Mor M. Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability. European Journal of Medicinal Chemistry. 46: 4466-73. PMID 21820769 DOI: 10.1016/J.Ejmech.2011.07.021 |
0.523 |
|
2010 |
Clapper JR, Moreno-Sanz G, Russo R, Guijarro A, Vacondio F, Duranti A, Tontini A, Sanchini S, Sciolino NR, Spradley JM, Hohmann AG, Calignano A, Mor M, Tarzia G, Piomelli D. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nature Neuroscience. 13: 1265-70. PMID 20852626 DOI: 10.1038/Nn.2632 |
0.516 |
|
2010 |
Eisenstein SA, Clapper JR, Holmes PV, Piomelli D, Hohmann AG. A role for 2-arachidonoylglycerol and endocannabinoid signaling in the locomotor response to novelty induced by olfactory bulbectomy. Pharmacological Research : the Official Journal of the Italian Pharmacological Society. 61: 419-29. PMID 20044005 DOI: 10.1016/J.Phrs.2009.12.013 |
0.509 |
|
2009 |
Clapper JR, Vacondio F, King AR, Duranti A, Tontini A, Silva C, Sanchini S, Tarzia G, Mor M, Piomelli D. A second generation of carbamate-based fatty acid amide hydrolase inhibitors with improved activity in vivo. Chemmedchem. 4: 1505-13. PMID 19637155 DOI: 10.1002/Cmdc.200900210 |
0.702 |
|
2009 |
Vacondio F, Silva C, Lodola A, Fioni A, Rivara S, Duranti A, Tontini A, Sanchini S, Clapper JR, Piomelli D, Mor M, Tarzia G. Structure-property relationships of a class of carbamate-based fatty acid amide hydrolase (FAAH) inhibitors: chemical and biological stability. Chemmedchem. 4: 1495-504. PMID 19554599 DOI: 10.1002/Cmdc.200900120 |
0.563 |
|
2009 |
Clapper JR, Mangieri RA, Piomelli D. The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology. 56: 235-43. PMID 18691603 DOI: 10.1016/J.Neuropharm.2008.07.018 |
0.7 |
|
2009 |
Vacondio F, Silva C, Lodola A, Fioni A, Rivara S, Duranti A, Tontini A, Sanchini S, Clapper JR, Piomelli D, Mor M, Tarzia G, King A. Cover Picture: Structure-Property Relationships of a Class of Carbamate-Based Fatty Acid Amide Hydrolase (FAAH) Inhibitors: Chemical and Biological Stability / A Second Generation of Carbamate-Based Fatty Acid Amide Hydrolase Inhibitors with Improved Activity in vivo (ChemMedChem 9/2009) Chemmedchem. 4: 1385-1385. DOI: 10.1002/Cmdc.200990041 |
0.667 |
|
2008 |
Justinova Z, Mangieri RA, Bortolato M, Chefer SI, Mukhin AG, Clapper JR, King AR, Redhi GH, Yasar S, Piomelli D, Goldberg SR. Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biological Psychiatry. 64: 930-7. PMID 18814866 DOI: 10.1016/J.Biopsych.2008.08.008 |
0.684 |
|
2008 |
Mor M, Lodola A, Rivara S, Vacondio F, Duranti A, Tontini A, Sanchini S, Piersanti G, Clapper JR, King AR, Tarzia G, Piomelli D. Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates. Journal of Medicinal Chemistry. 51: 3487-98. PMID 18507372 DOI: 10.1021/JM801482Q |
0.672 |
|
2007 |
King AR, Duranti A, Tontini A, Rivara S, Rosengarth A, Clapper JR, Astarita G, Geaga JA, Luecke H, Mor M, Tarzia G, Piomelli D. URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices. Chemistry & Biology. 14: 1357-65. PMID 18096504 DOI: 10.1016/J.Chembiol.2007.10.017 |
0.682 |
|
2007 |
Tarzia G, Antonietti F, Duranti A, Tontini A, Mor M, Rivara S, Traldi P, Astarita G, King A, Clapper JR, Piomelli D. Identification of a bioactive impurity in a commercial sample of 6-methyl-2-p-tolylaminobenzo[d][1,3]oxazin-4-one (URB754). Annali Di Chimica. 97: 887-94. PMID 17970304 DOI: 10.1002/Adic.200790073 |
0.628 |
|
2006 |
Clapper JR, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D. The fatty-acid amide hydrolase inhibitor URB597 does not affect triacylglycerol hydrolysis in rat tissues. Pharmacological Research : the Official Journal of the Italian Pharmacological Society. 54: 341-4. PMID 16935521 DOI: 10.1016/J.Phrs.2006.06.008 |
0.575 |
|
Show low-probability matches. |